Chimerix, Inc.(CMRX), a biopharmaceutical company, is planning to submit a New Drug Application to the FDA for accelerated approval of Dordaviprone as a treatment for recurrent H3 K27M-mutant diffuse glioma by the end of 2024.
H3 K27M-mutant diffuse glioma is an aggressive and often fatal form of brain cancer that affects more than 2,000 patients annually in the U.S. This type of glioma is very difficult to treat, with limited therapeutic options available for patients.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.